National Bowel Cancer Screening Program Monitoring Report
Screening participants diagnosed with bowel cancer had a lower risk of dying from it, and modelling suggests wider participation could cut deaths by up to 59%.
KEY FINDINGS
The National Bowel Cancer Screening Program (NBCSP) mails free, at-home immunochemical faecal occult blood test (iFOBT) kits to eligible Australians aged 50 to 74 every two years. The Australian Institute of Health and Welfare monitors the program by linking participation data to cancer and death registries, allowing it to measure the program's real-world effect on diagnosis stage and mortality, not just how many people take part.
AIHW data linkage studies found that people invited to screen, and particularly those who participated, who were later diagnosed with bowel cancer had a lower risk of dying from the disease and were more likely to be diagnosed at a less advanced stage than people who did not participate.
Modelling suggests the program could reduce bowel cancer mortality by 36% at the current participation rate of around 40%, rising to 59% if participation reached 70%. A separate independent analysis estimated the program would prevent roughly 2,300 to 3,200 bowel cancer deaths per year between 2015 and 2040.
What sets this apart from most screening claims is that the benefit was measured, not modelled. It shows up in real, linked data on how advanced the cancer was at diagnosis and how many people survived it.
That is the whole case for cancer-focused screening, captured in one national program: when disease is found earlier, outcomes measurably improve.
